Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
HUTCHMED (China) ( (HK:0013) ) just unveiled an announcement.
HUTCHMED and Innovent, both major players in oncology-focused biopharmaceuticals, have built portfolios around targeted therapies and immunotherapies, including the VEGFR inhibitor fruquintinib (ELUNATE) and the PD‑1 antibody sintilimab (TYVYT). Their partnership reflects a broader push in China to expand access to advanced cancer treatments and integrate locally developed drugs into global oncology standards.
The companies announced that China’s NMPA has approved ELUNATE in combination with TYVYT for second-line treatment of locally advanced or metastatic renal cell carcinoma in patients previously treated with VEGFR‑TKIs but not with PD‑1/PD‑L1 inhibitors. The approval, based on the FRUSICA‑2 Phase III trial showing a 63% reduction in risk of progression or death and markedly longer progression-free survival versus axitinib or everolimus, strengthens HUTCHMED’s and Innovent’s positions in China’s kidney cancer market and underscores the growing clinical role of this regimen, which now has approvals in two hard-to-treat cancers.
More about HUTCHMED (China)
HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on discovering, developing and commercializing targeted therapies and immunotherapies for cancer and immunological diseases. It advances drug candidates from in-house discovery to global markets, with three medicines already marketed in China and one also approved in the U.S., Europe and Japan.
For detailed information about 0013 stock, go to TipRanks’ Stock Analysis page.